ArticleFrontiers in oncology2022

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.